Myrobalan Therapeutics’ Post

With over $1 billion in committed capital, Xaira Therapeutics launched yesterday to re-engineer drug R&D through emerging AI tools. 🚀  Co-founded by our partner Foresite Labs, ARCH Venture Partners, and Dr. David Baker, Professor of Biochemistry and Director of the Institute for Protein Design, University of Washington, Xaira is led by founding CEO and renowned scientist Dr. Marc Tessier-Lavigne, former Chief Scientific Officer of Genentech and former President of Rockefeller and Stanford Universities. 👨🏼🔬With an all-star team on board, they’re driving advances in AI to learn the language of life and transform how we treat disease. “If you asked an AI to generate a brand-new drug discovery biotech with a team of some of the biggest names in the biz for you, it couldn’t dream up one like Xaira Therapeutics.” It’s been an honor helping tell Xaira’s story and we can’t wait to see what they achieve. This is only the beginning! 💪 Learn more about how Xaira Therapeutics is creating faster paths to treatment via Fierce Biotech and Annalee Armstrong: https://bit.ly/3Wel1uB CC: Vik Bajaj, Cindy Lundin Mesaros, Kayla Abbassi, Vijay Chattha, Morgan Warners, Kim James, Olivia Z. #foresitecapital #foresitelabs #AI #xairatherapeutics

𝗦𝘆𝗩𝗲𝗻𝘁𝗼 𝗕𝗶𝗼𝗧𝗲𝗰𝗵 & 𝗡𝗼𝗿𝘁𝗵𝗲𝗿𝗻 𝗥𝗡𝗔: 𝗔 𝗣𝗼𝘄𝗲𝗿𝗳𝘂𝗹 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝗳𝗼𝗿 𝗺𝗥𝗡𝗔 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀! SyVento BioTech is thrilled to announce an extended collaboration with Northern RNA Inc. A leading provider of CAP analogs and plasmid DNA! This exciting partnership offers significant benefits for both companies and, ultimately, accelerates progress in the field of #mRNATherapeutics. 𝗞𝗲𝘆 𝗘𝗹𝗲𝗺𝗲𝗻𝘁𝘀 𝗼𝗳 𝘁𝗵𝗲 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻: ✔️ Together, we will explore collaborative scientific and development projects. ✔️ Together, we will leverage our combined expertise to unlock new possibilities in mRNA therapeutics leading to more effective, safer and better tolerated treatments. ✔️ Together, we will be furthering industry knowledge from joined projects. ✔️ Together, we enhance product delivery efficiency by capitalizing on each other’s abilities.  ✔️ Together, we will enhance each other's product delivery capacity, allowing both of us to deliver products more efficiently.  ✔️ Together, we will benefit from the regulatory expertise of each other’s teams. This collaboration represents a significant step forward for SyVento BioTech and Northern RNA Inc. Together, we are committed to providing researchers and developers with the tools and expertise needed to advance the next generation of mRNA therapies. #SyventoBioTech #NorthernRNA #MRNATherapeutics #Collaboration #Innovation #Partnerships

🔬 Just wrapped up an incredible experience at the xRNA Therapeutics Development and Innovation Forum 2024! 🌐 Grateful for the opportunity to participate in this cutting-edge conference, where over 1000 professionals converged to explore the latest trends and innovations in biotech drug development. 🚀 Key Takeaways: 💡 Explored advancements in mRNA/circRNA vaccine/drug development. 🤖 Discovered the role of AI in accelerating mRNA research. 🌱 Explored emerging trends in oligonucleotide drug development. Notable Moments: Engaging discussions on mRNA delivery strategies and quality control. Insightful presentations by industry leaders on CRISPR/Cas9 applications and mRNA nano-tumor vaccines. Gratitude: Huge thanks to Deliver Life Sciences and all supporting units for organizing this impactful event! 🙌 Looking Forward: Excited to bring these insights back to the team and explore potential collaborations in line with the discussed strategies. The future of biotech is indeed thrilling! 🌟 #Biotech #DrugDevelopment #Innovation #Networking #ConferenceExperience #LinkedInPost

🙏 Thanks to Speedinvest & Dealroom.co for having identified ADLIN Science as one of the companies in the area of Data Infrastructure and more concrete as an enabling technology necessary for Techbio companies in drug discovery. 🔬 We have the objective to unlock health data to accelerate drug discovery & development by enabling Techbio companies the access to deep data to train and optimize their AI models. 🤝 By being positioned between health public institutions, Techbio companies and AI solution providers, ADLIN aims to accelerate and derisk AI projects for Pharma companies and Biotechs.  💡 Our Decentralized Research Environment can do precisely this by providing the tools necessary to make data better structured & interoperable to accelerate its access & analysis to generate insights. Our initial focus is Childhood Cancers due to the great unmet needs in developing first-in-child drugs, but our technology and expertise are also aimed at Adult Oncology & Rare diseases. 👍 Thanks Estelle & Daria for the great report! Link here: https://lnkd.in/ews4rrB8 Do not hesitate to connect with us if you want to know more. #theADLINway #PrecisionMedicine #ChildhoodCancers BioLabs France | Genopole | PariSanté Campus | Agoranov

Latest DON Therapeutics news The biotechnology sector finds itself at a critical juncture, fueled by rapid technological advancements and evolving market dynamics. Recent years have witnessed transformative breakthroughs reshaping healthcare, drug development, and beyond, with innovations spanning from AI to RNA technology. AI's Impact on Biotech The advent of AI has revolutionized the biotech landscape, sparking a surge in applications across the Biopharma sector. From drug and protein discovery to treatment repurposing, AI has ushered in a new era of innovation, driving unprecedented advancements. Advancements in RNA Technology The field of RNA technology has evolved significantly, encompassing a range of RNA-based therapies. These include single and double-stranded RNA molecules such as mRNAs, miRNAs, siRNAs, and antisense RNAs, each offering distinct mechanisms and applications. From immunotherapy to disease treatment, these advancements mark a new frontier in biotech innovation. We are always seeking healthcare opportunities at DON Therapeutics become a part of a community designed to accelerate your growth Submit your opportunity via this link - https://lnkd.in/dcvSMynH For more information visit DON Therapeutics - www.don-therapeutics.com #medtech #biotech #ceos #investors

🔬💊 Exciting News! CRISPR is revolutionizing drug discovery! 🚀 🧬 Over the past few years, this incredible technology has transformed the drug discovery process, taking it to a whole new level of efficacy, safety, and specificity. 🎯 💡 Imagine being able to identify the key genes responsible for certain diseases. Well, with CRISPR-based screens, we can! 🧪 These genome-wide screens help us pinpoint those crucial genes for disease phenotypes, bringing us one step closer to finding effective treatments. 💪 But it doesn't stop there! CRISPR technologies can be incorporated into every stage of drug discovery. From target identification to therapeutic delivery, CRISPR-Cas components are here to save the day! 🔍 This means we can now develop novel therapeutics with improved precision, making them safer and more effective for patients. 🌐 Stay tuned for more updates as we explore the endless possibilities of CRISPR in revolutionizing medicine! https://hubs.li/Q02gw9qf0 #CRISPR #DrugDiscovery #RevolutionizingMedicine #GameChanger #PrecisionTherapeutics

Are you ready to accelerate your drug discovery with AI-driven solutions designed to minimize risk and maximize results? At Syntekabio we are investing in your success with our unique Develop Now, Pay Later offer - enabling fast hit and lead discovery, allowing you to focus on achieving breakthroughs. Start today with a complimentary feasibility study of your target proteins! 🧬 Benefit from: •In-depth evaluation: Leverage our advanced AI and supercomputing technology to assess the viability of your targets without any upfront costs. •Key insights: Gain valuable data on your compounds' potential, helping you make informed decisions before committing resources. •No financial commitment: You only pay once you obtain the agreed upon validated results 📋 Contact us today to schedule your complimentary Feasibility Study and accelerate your drug discovery process: https://lnkd.in/eXC4EuiF #DrugDiscovery #Clinical #Oncology #Biotechnology #Pharma #AI #Syntekabio

What are some biotech companies to know about in the Boston area? 💼 The Boston region in the U.S. state of Massachusetts (MA) hosts one of the leading biotech hubs in the world. With significant VC firms in the region as well as world-leading biotech companies such as Vertex Pharmaceuticals, the Boston region shows no signs of slowing down. 📈 Discover 12 companies to know about in the Boston region in our latest article! ⬇️ https://lnkd.in/dZ38dysT #bostonbiotech #biotechcompanies #biotechhub #VCinvestment #biotechinnovation #lifesciences #bostontech #biotechresearch #startupscene Akouos | Cellarity | ElevateBio | Emulate, Inc. | Life Biosciences | MOMA Therapeutics | Neumora | Orna Therapeutics | Sail Biosciences | Laronde | Senda Biosciences | Tessera Therapeutics | Wave Life Sciences | XtalPi Inc.

Biopharma's Evolution: Precision medicine and gene therapies reshape healthcare. Strategic investments by venture capitalists translate research into transformative solutions, positioning us as architects of a healthier future. #pharma #pharmaceutical #healthcare #venturecapital #investment #biopharma

Wrapped up in our coziest coats, we unwrapped an early Christmas present at the Advanced Therapies Integrates 2023 event in a frosty Stevenage, UK. Huge thanks to the organizers, Life Science Integrates, and supporters including Stevenage Bioscience Catalyst, Cytiva, and Cell and Gene Therapy Catapult, among others, for orchestrating this focused networking event that seamlessly brought together stakeholders spanning the entire drug development cycle. Amidst delightful coffee and delicious food, we engaged with representatives from big pharma, patient advocates, CDMOs, fellow consultants, clinicians, researchers, early-stage developers, biotech and pharma professionals, regulators, market access experts, and various other industry players. Hot topics of discussion included closed systems and automation, with a common agreement that well-characterized, consistent processes are prerequisites for successful automation. The discussion also delved into exciting applications of AI and advanced software to support the NHS workforce and enhance operational efficiencies, with a caveat for cautious implementation. Gene People and Opie Jones Foundation brought invaluable patient perspectives into the discourse, emphasizing that the costs of new therapies should consider the alternatives of no or limited treatment options. Cytiva and the Cell and Gene Therapy Catapult provided lab tours, offering developers insights into processes and feasibility before embarking on manufacturing runs. This aids in cost management and risk mitigation. Investors, beyond seeking breakthrough science, actively seek enthusiasm, perseverance, and responsiveness in early-stage biotechs. The imperative of closely tracking your company’s value and inflection points was underscored. Understanding the investor perspective involves placing yourself in their shoes. Lindville Bio shared insights into iPSC therapeutic development. With sights set on the horizon, we eagerly anticipate the next edition of Advanced Therapies Integrates in 2024! #Advancedtherapiesintegrates2023 #Biotech #DrugDevelopment #Innovation #networkingsuccess #iPSC #stemcells #celltherapy #regenerativemedicine #biotech #biotechnology #lifescience #advancedtherapies #ATMP #genetherapy #raredisease #pharma #pharmaceuticals #biopharma